Leg-Reg Briefing October 2018: CMS Releases Star Ratings for 2019 Part D Plans; New Proposed Rule on Drug Prices in DTC TV Ads; House, Senate Recess Until After Midterms
AMCP CEO Blog: As managed care pharmacy professionals, we work to improve the lives of millions of people. But we also must never forget that behind these large numbers are individual patients.
Opioid Legislation Reaches Final Agreement--September 2018 With a final compromise bill for the opioid package announced, AMCP would like to thank its members who acted to advocate for the inclusion of provisions which will help managed care combat the opioid crisis. Almost 300 AMCP members sent letters to 62 Senators
Partnership Forum: Combating rising health care costs and taking advantage of new pharmaceutical innovations to improve patient outcomes, all while lowering the total cost of care, is a challenge in today’s health care system. AMCP brought together thought leaders in September 2018 to discuss the issues and solutions needed on this key issue.
On September 21, 2018, AMCP offered comments to the FDA on facilitating biosimilar adoption and the interchangeability designation. Comments focused on interchangeability guidance, naming conventions, and collection of post-marketing real-world evidence by partnering with organizations such as Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).
The Academy of Managed Care Pharmacy (AMCP) thanks Congress for its dedication to combatting the opioid epidemic. The importance of H.R. 6 increases as the number of preliminary CDC reported overdose deaths rise (72,000 overdose deaths in 2017). Both pieces of legislation passed by the House and Senate will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and increase education initiatives for patients and providers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments” as published in the Federal Register on July 25, 2018.